+Vote!
Seeking Alpha (Free subscription) | 08/14/2008
Mike Huckman submits: The market cap of Dow component Johnson & Johnson (JNJ) is a whopping $200 billion. Abbott Labs (ABT) is valued at less than half that. But think of Abbott as a kind of mini-me JNJ because like Johnson & Johnson, ABT has cobbled together a similar three-siloed business of drugs, devices and consumer products. Complete Story »
1Vote!
Chicago Tribune (Free subscription) | 08/04/2008
SAN FRANCISCO (AP) _ When Abbott Laboratories Inc. hiked up the price of a popular AIDS drug by 400 percent in 2003, executives prepared for the inevitable public relations hit, but assured themselves the backlash would be brief.
+Vote!
Star Tribune (Free subscription) | 08/04/2008
The lawsuits, all filed in Oakland federal court, accuse Abbott of raising the price of the HIV-fighting Norvir to illegally stifle competition and boost sales of its own alternative, Kaletra. Embarrassing internal communications between executives plotting how to thwart their rivals in the lucrative HIV drug cocktail market have been made public in the process.
+Vote!
Kiplinger Personal Finance (Free subscription) | 08/06/2008
The market isn't fully appreciating this health care company's well-diversified product lines and near-term profitability strength.
1Vote!
Medical,Health News and Articles (Free subscription) | 08/04/2008
Pharmaceutical News Abbott Laboratories width=396 align=left vspace=5 border=0> This article is republished with kind permission from our friends at The Kaiser Family Foundation. You can view the entire Kaiser Daily Health Policy Report, search the archives, or [...]
+Vote!
Seeking Alpha (Free subscription) | 07/16/2008
Mike Havrilla submits: Abbott Labs (ABT) posted better than expected earnings and sales growth and raised its guidance this morning, reflected in the 1-year stock chart posted on my blog which shows that the company has outperformed the S&P 500 index by over 30% and the Healthcare Sector SPDR exchange-traded fund (XLV) by over 20%. Results included the following: Complete Story »
+Vote!
ICKPLUS (Free subscription) | 07/16/2008
Abbott Reports Stronger-than-Expected Sales and Earnings Growth in Second Quarter and Raises Full-Year Outlook Worldwide Sales Increased 14.8 Percent Adjusted EPS Growth of 21.7 Percent (GAAP up 34.9 Percent) Worldwide Pharmaceutical Sales Increased 16.7 Percent Worldwide Medical Products Sales Increased 14.7 Percent Eight New Regulatory Approvals Received Year-to-Date Company Raises Full-Year Sales...
+Vote!
Market Watch (Free subscription) | 07/16/2008
TEL AVIV (MarketWatch) -- Abbott Laboratories, the Abbott Park, Ill., health-care giant, reported second-quarter net income rose 34% on 15% higher sales. Earnings reached $1.32 billion, or 85 cents a share, from $988.7 million, or 63 cents, in the year-earlier period. Excluding special items, the earnings were 84 cents against 69 cents. Sales rose to $7.31 billion from $6.37 billion. A survye of analysts...
1Vote!
EuroInvestor.co.uk (Free subscription) | 07/15/2008
... The Courts ruling clears the last remaining hurdle for the plaintiffs to seek restitution for Abbott Labs violations of federal law that caused 10,000 people to lose valuable retirement benefits, said Steven Sprenger, counsel for the plaintiffs at the law firm Sprenger + Lang. We are anxious to get this case to trial as quickly as possible.To reach this stage, plaintiffs have had to overcome...
1Vote!
Pharmalot (Free subscription) | 08/18/2008
Company 2007 2012 Percent Change Schering-Plough 0.38 1.58 315.8% Amgen 4.50 1.46 -67.6% Bristol-Myers Squibb 1.08 0.84 -21.7% Wyeth 0.60 0.49 -18.2% Abbott Labs 1.73 0.42 -75.7% Johnson & Johnson 0.39 0.38 -2.4% GlaxoSmithKline 0.27 0.32 17.3% Eli Lilly 6.64 0.29 -95.6% Novartis 2.27 0.27 -88.2% Merck 0.51 0.26 -49.0% Pfizer 0.39 0.06 -85.7% AstraZeneca 0.58 0.04 -92.6% Roche 4.03 0.00 -100.0%...
- send to a friend
-
Explore : Amgen, Biotechnologies, Bristol, Bristol-Myers Squibb, Drug Manufacturers, Eli Lilly, Glaxosmithkline, Health Care Policy, Novartis, Schering-Plough, Wyeth
+Vote!
The Street (Free subscription) | 07/03/2008
Abbott climbs on an FDA approval of its Xience V stent.
+Vote!
Business Week (Free subscription) | 07/03/2008
Plus more stocks making headlines in Thursday's market
+Vote!
Business Week (Free subscription) | 07/03/2008
Analyst opinions on stocks making headlines in Thursday's market
+Vote!
Star Tribune (Free subscription) | 07/03/2008
The Food and Drug Administration's blessing for the drug-coated Xience stent could generate billions of dollars for the company.
+Vote!
Market Watch (Free subscription) | 07/02/2008
In a move widely anticipated by industry watchers, the Food and Drug Administration has approved Abbott Laboratories and Boston Scientific’s new drug-coated coronary stent.
